Ocular manifestations | ||||||
| Yes | No | Total | OR (IC 95%) | p value | |
N = 28 | N = 25 |
|
| |||
Variables | n (%) | n (%) | n (%) | |||
Sex |
|
|
|
|
| |
Male | 15 (53.6) | 13 (46.4) | 28 (52.8) | 1.07 (0.35 - 3.2) | 0.560 | |
Female | 13 (52) | 12 (48) | 25 (47.2) | 0.94 (0.31 - 2.83) | 0.560 | |
Age (ans) |
|
|
|
|
| |
[5 - 10] | 9 (60) | 6 (40) | 15 (28.3) | 1.5 (0.44 - 5.33) | 0.360 | |
[10 - 15] | 10 (66.7) | 5 (33.3) | 15 (28.3) | 2.22 (0.63 - 8.33) | 0.170 | |
[15 et + ] | 9 (39.1) | 14 (60.9) | 23 (43.4) | 0.37 (0.12 - 1.16) | 0.070 | |
Duration of treatment (years) | ||||||
[0 - 5] | 6 (75) | 2 (25) | 8 (15.1) | 3.14 (0.58 - 24.16) | 0.160 | |
[5 - 10] | 14 (53.8) | 12 (46.2) | 26 (49.1) | 1.08 (0.36 - 3.26) | 0.550 | |
[10 et Plus] | 8 (42.1) | 11 (57.9) | 19 (35.8) | 0.51 (0.16 - 1.63) | 0.190 | |
CD4 (cell) count |
|
|
|
|
| |
[20 - 200] | 2 (100) | 0 (0) | 2 (3.8) | - | 0.270 | |
[200 - 350] | 2 (100) | 0 (0) | 2 (3.8) | - | 0.270 | |
[350 - 450] | 3 (75) | 1 (25) | 4 (7.5) | 2.88 (0.28 - 78.76) | 0.350 | |
[500 et + ] | 21 (46.7) | 24 (53.3) | 45 (84.9) | 0.13 (0.01 - 0.93) | 0.040 | |
Viral load (particles) | ||||||
0 | 20 (57.1) | 15 (42.9) | 35 (66) | 1.67 (0.52 - 5.4) | 0.280 | |
[1 - 100,001] | 5 (45.5) | 6 (54.5) | 11 (20.8) | 0.69 (0.17 - 2.74) | 0.420 | |
[10,001 - 50,000] | 1 (33.3) | 2 (66.7) | 3 (5.7) | 0.43 (0.01 - 6) | 0.460 | |
[50,001 et + ] | 2 (50) | 2 (50) | 4 (7.5) | 0.88 (0.09 - 9.09) | 0.650 | |